DrugPatentWatch Database Preview
Msd Merck Co Company Profile
» See Plans and Pricing
What is the competitive landscape for MSD MERCK CO, and what generic alternatives to MSD MERCK CO drugs are available?
MSD MERCK CO has seven approved drugs.
There are four US patents protecting MSD MERCK CO drugs.
There are one hundred and sixty-four patent family members on MSD MERCK CO drugs in forty-nine countries and sixty-three supplementary protection certificates in fourteen countries.
Summary for Msd Merck Co
| International Patents: | 164 |
| US Patents: | 4 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 7 |
Drugs and US Patents for Msd Merck Co
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msd Merck Co | DELSTRIGO | doravirine; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 210807-001 | Aug 30, 2018 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Msd Merck Co | ZOCOR | simvastatin | TABLET;ORAL | 019766-005 | Jul 10, 1998 | AB | RX | Yes | Yes | Start Trial | Start Trial | ||||
| Msd Merck Co | DELSTRIGO | doravirine; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 210807-001 | Aug 30, 2018 | RX | Yes | Yes | 8,486,975 | Start Trial | Y | Y | Start Trial | ||
| Msd Merck Co | PIFELTRO | doravirine | TABLET;ORAL | 210806-001 | Aug 30, 2018 | RX | Yes | Yes | 8,486,975 | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Msd Merck Co
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Msd Merck Co | ZOCOR | simvastatin | TABLET;ORAL | 019766-001 | Dec 23, 1991 | 4,444,784*PED | Start Trial |
| Msd Merck Co | ZOCOR | simvastatin | TABLET;ORAL | 019766-003 | Dec 23, 1991 | 4,444,784*PED | Start Trial |
| Msd Merck Co | ZOCOR | simvastatin | TABLET;ORAL | 019766-005 | Jul 10, 1998 | RE36520*PED | Start Trial |
| Msd Merck Co | EMEND | aprepitant | FOR SUSPENSION;ORAL | 207865-001 | Dec 17, 2015 | 6,096,742 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MSD MERCK CO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 115 mg/vial | ➤ Subscribe | 2012-01-25 |
| ➤ Subscribe | for Oral Suspension | 125 mg/Kit | ➤ Subscribe | 2016-11-23 |
| ➤ Subscribe | Chewable Tablets | 4 mg and 5 mg | ➤ Subscribe | 2006-12-26 |
| ➤ Subscribe | Capsule | 40 mg, 80 mg and 125 mg | ➤ Subscribe | 2008-11-03 |
| ➤ Subscribe | Injection | 150 mg/vial | ➤ Subscribe | 2012-01-25 |
| ➤ Subscribe | Tablets | 10 mg | ➤ Subscribe | 2007-02-20 |
International Patents for Msd Merck Co Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 201005333 | Start Trial |
| Israel | 222030 | Start Trial |
| Croatia | P20131123 | Start Trial |
| Croatia | P20150427 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Msd Merck Co Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2552902 | PA2019506,C2552902 | Lithuania | Start Trial | PRODUCT NAME: DORAVIRINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1332 20181122 |
| 2924034 | C201930027 | Spain | Start Trial | PRODUCT NAME: DORAVIRINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA EN COMBINACION CON LAMIVUDINA Y TENOFOVIR DISOPROXILO FUMARATO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1333; DATE OF AUTHORISATION: 20181122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1333; DATE OF FIRST AUTHORISATION IN EEA: 20181122 |
| 2666774 | PA2020517 | Lithuania | Start Trial | PRODUCT NAME: RELEBAKTAMAS, PASIRINKTINAI MONOHIDRATO PAVIDALU, IR IMIPENEMAS; REGISTRATION NO/DATE: EU/1/19/1420 20200213 |
| 0720599 | C300172 | Netherlands | Start Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN SIMVASTATINE; NAT. REGISTRATION NO/DATE: RVG 30927RVG 30928RVG 30929RVG 30930 2004221122; FIRST REGISTRATION: 58874.00.0058874.01.0058874.02.0058874.03.0058878.00.0058878.01.0058878.02.0058878.03.0058866.00.0058866.01.0058866.02.0058866.03.0058870.00.0058870.01.0058870.02.0058870.03.00 2004020402 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
